[EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY]

What Was Tested

Researchers studied Bradykinin and Icatibant in this phase 3 clinical trial publication.

This study investigated icatibant, a selective bradykinin B2 receptor antagonist, as treatment for Japanese patients with an acute HAE attack.

Why It Was Studied

Hereditary angioedema (HAE) is characterized by paroxysmal edema of the skin, gastrointestinal mucosa, and upper respiratory tract.

Who Took Part

According to the abstract, 3 adults were involved.

The age groups tagged for this paper are middle-aged adults, both men and women.

This was an open-label, single-arm, Phase 3 study of Japanese adults with HAE type I or II.

How the Study Was Run

In design terms this was an open-label study.

Nothing was hidden in this open-label Bradykinin study: the adults and staff both knew the treatment.

What Was Measured

Hereditary angioedema (HAE) is characterized by paroxysmal edema of the skin, gastrointestinal mucosa, and upper respiratory tract.

PubMed files the paper under topics including Acute Disease, Angioedemas, Hereditary, Anti-Inflammatory Agents, Non-Steroidal and Bradykinin.

The authors tagged it with the keywords Japan, bradykinin B2 receptor antagonist, hereditary angioedema Types I and II, icatibant and phase III clinical trial.

What This Means in Plain Language

The paper is an open-label study of Bradykinin and Icatibant in 3 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Arerugi = [Allergy]), a journal based in Japan.

More context: the Bradykinin compound page and the Icatibant compound page, all human trials.